Organ-specific autoimmune diseases are caused by clones of autoimmune effector T lymphocytes that attack the otherwise normal tissues of the individual (1) . Accordingly, it should be possible to treat autoimmune processes by inducing an immune response specifically directed against the pernicious autoimmune effector clones.
This idea was realized experimentally when we isolated lines and clones of autoimmune helper T lymphocytes capable of causing various autoimmune diseases in rats or mice (2, 3) . It was observed that some of these T lymphocytes, made avirulent by irradiation, could be used to induce resistance to specific autoimmune diseases produced by virulent autoimmune T lymphocytes of similar specificity (4, 5) .
The present report relates to adjuvant arthritis, a disease that is induced in susceptible strains of rats with Mycobacterium tuberculosis in oil, a mixture known as complete Freund's adjuvant (6) . Helper T lymphocytes were raised as lines and clones by immunizing Lewis strain rats with M. tuberculosis and selecting M. tuberculosis-specific T lymphocytes in vitro (7) . One clone, designated A2b, was found to produce arthritis in irradiated Lewis rats (8) . This clone proliferated in vitro in response to an epitope of M. tuberculosis, but also reacted to the proteoglycan ofjoint cartilage (9) . Thus, arthritogenic A2b identified a shared epitope between M. tuberculosis and a self-component ofthejoint, an epitope that explained how a foreign bacterial antigen could induce an autoimmune disease (10) . Helper T-lymphocyte responses to the cross-reactive M. tuberculosis antigen also have been detected in the peripheral blood and synovial fluid of rheumatoid arthritis patients (11) . Autoimmune clone A2b, irradiated or not, did not induce resistance to active adjuvant arthritis (8) .
Our aim was to learn how clone A2b and other T lymphocytes might be converted into specific vaccines against autoimmunity. We reasoned that vaccination might be enhanced by measures that augmented the immunogenicity of clone A2b. It was discovered in the Shinitzky laboratory that the immunogenicity ofleukemia antigens could be augmented by treating the tumor cells with hydrostatic pressure in vitro (12) . Under hydrostatic pressure the lipid bilayer becomes more rigid, thereby causing aggregation and greater exposure of membrane components (13) . For this reason, we applied hydrostatic pressure to A2b and other autoimmune lymphocytes with the objective of enhancing their capacity to trigger an immune response (14) .
MATERIALS AND METHODS
Rats. Rats of the inbred Lewis strain were bred at this institute. They were used at the age of 2-4 months and were matched for age and sex in each experiment.
Induction of Disease. Adjuvant arthritis was induced as described (7) . Briefly, rats were inoculated subcutaneously at the base of the tail with 0.1 ml of oil (incomplete Freund's adjuvant) to which was added 1 mg of M. tuberculosis. Adjuvant arthritis usually appeared about 13 days later. The degree of clinical arthritis was scored by estimating the swelling and redness of each of the four limbs on a scale of 1-4 as described (7, 8) . The scores of each of the four limbs were added to obtain a maximum of 16 for any rat. The relative score was computed on the base of 100 for the maximum of 16. Experimental autoimmune encephalomyelitis was induced as described (2, 3 (8) .
Helper T-lymphocyte line Zia (CD4', CD8-) was obtained as described (2) . Activated Zia (106 cells) was encephalitogenic in naive Lewis rats. It was shown to recognize an epitope from amino acids 68-88 of guinea pig or rat myelin basic protein (15) . Zia appears, indeed, to be a clone as indicated by a distinct and uniform rearrangement of its antigen receptor genes (unpublished results). A2b or Zia was activated by incubation for 3 days with M. tuberculosis (50 Ag/ml) or myelin basic protein (25 ,ug/ml), respectively, or with the mitogen Con A at 2.5 /ig/ml and irradiated (1500 R) syngeneic thymus cells, which contain a population of antigen-presenting cells. The lymphoblasts were isolated by Ficoll density centrifugation and used for vaccination.
Vaccination. Activated T-lymphocyte clones or populations of lymph node cells were used. For pressure treatment, the T lymphocytes (108 cells) were placed in 1.5 ml of cold (40C) phosphate-buffered saline (PBS) in an Eppendorf centrifuge tube as described (14) . The tube was filled with fluid to avoid trapped bubbles, and a short 21-gauge disposable syringe needle was pushed through the cap of the tube to equalize pressure. The tube was then introduced into a pressure cylinder (American Instrument, Silver Spring, MD) filled with cold (40C) PBS. Pressure was applied slowly (for 4-5 min) using a French press to a level of 1250 bars (1 bar = 105 Pa) for 15 min. Thereafter, the pressure was slowly released (for 4-5 min). This degree of hydrostatic pressure was found in dose-response experiments to be optimal for vaccination. About 90% of the treated cells excluded the dye trypan blue. Rats were inoculated with 1-2 x i07 T lymphocytes three times at weekly intervals. One week after the last inoculation, or as otherwise stated, the rats were challenged with myelin basic protein (25 ,ug) or M. tuberculosis (1 mg) in adjuvant to induce active experimental autoimmune encephalomyelitis (3) or adjuvant arthritis (7), respectively, to assess the development of resistance to disease. Therapy of adjuvant arthritis was done by first inducing the disease and then treating the rats with one to three inoculations of pressure-treated cells. Vaccines were administered subcutaneously, intravenously, or intraperitoneally as indicated. The effect of vaccination did not seem to be influenced by the administration route used.
Cross-linking of membrane components was done by incubating 108 T lymphocytes in 5 ml of gluteraldehyde (0.3% in PBS) at room temperature for 15 min. The treated T lymphocytes were washed six times by centrifugation in 50 ml of PBS and used for vaccination as described above.
Disruption of the cytoskeleton of T lymphocytes was done by incubating the cells at room temperature for 15 min in a mixture of colchicine (10 mmnol) and cytochalasin B (0.5 ,ug/ml) in PBS. The cells were washed and used for vaccination as described above.
Delayed-Type Hypersensitivity. Lewis rats were vaccinated and then 1 month later were challenged by subcutaneous inoculation into the pinna of 3 x 105 activated, irradiated (2500 R) T-lymphocyte clonal cells in 50 ,u/ of PBS. Swelling of the ear was determined after 48 hr using an isotonic caliper. Histologic examination of the ear swelling confirmed the diagnosis of a delayed-type hypersensitivity reaction. Vaccination with pressure-treated T lymphocytes was immunologically specific; A2b-vaccinated rats resistant to adjuvant arthritis were susceptible to induction of experimental autoimmune encephalomyelitis by immunization with myelin basic protein in adjuvant (data not shown).
RESULTS
The effectiveness of pressure-treated clones in preventing adjuvant arthritis led us to test their ability to induce remission in rats with established adjuvant arthritis. Rats were immunized with M. tuberculosis and 15 days later, when all were suffering from arthritis, groups of rats were treated by a single intraperitoneal inoculation of 2 x 107 pressure-treated control Zia or A2b cells. Fig. 1 shows that inoculation of rats with Zia did not affect the natural course of arthritis. However, the extent of disease was markedly reduced in the rats that had been inoculated with pressuretreated A2b cells. Thus, exposure of arthritogenic clone A2b to hydrostatic pressure rendered it avirulent and turned it into an agent for preventing or treating adjuvant arthritis.
Because A2b-like clones were probably present in rats primed in vivo, we tested whether vaccination could be achieved using pressure-treated lymph node cells obtained directly from immunized rats. Rats were immunized either with myelin basic protein or M. tuberculosis, and 9 days later the draining lymph nodes were removed, and the cells were activated by culture with the T-lymphocyte mitogen Con A. The activated lymph node cells were then exposed to hydrostatic pressure and inoculated into naive rats. The rats were challenged either with myelin basic protein or M. tuberculosis to test their susceptibility to active adjuvant arthritis or to experimental autoimmune encephalomyelitis. Table 2 shows that activated pressure-treated control lymph node cells or lymph node cells from rats primed with M. tuberculosis did not immunize rats for experimental autoimmune encephalomyelitis. However, activated, pressure-treated lymph node cells from rats primed with myelin basic protein induced resistance to experimental autoimmune encephalomyelitis. In contrast to experimental autoimmune encephalomyelitis, resistance to adjuvant arthritis was induced by vaccination with activated pressure-treated lymph node cells from M. tuberculosis-primed rats. Hence, populations of cells containing antigen-specific T lymphocytes could be used as specific vaccines following activation and exposure to hydrostatic pressure. Fig. 2 shows that activated, pressure-treated lymph node cells could be used to treat established adjuvant arthritis. Control lymph node cells similarly activated and pressure treated were not therapeutic.
As the antigen specificity of the vaccinating T cells influenced the specificity of the resistance to disease, it was ,ug/ml) and then treated with hydrostatic pressure (1250 bars). Groups of 20 rats were vaccinated subcutaneously with 2 x 107 cells at weekly intervals for 3 weeks. One week later, the rats were challenged with myelin basic protein or M. tuberculosis to induce experimental autoimmune encephalomyelitis or adjuvant arthritis, respectively.
conceivable that vaccination might involve the induction of immunity to the autoimmune receptors of the vaccine (5, 16).
To test this hypothesis, we investigated the delayed-type hypersensitivity responses of vaccinated rats to particular T-lymphocyte clones. Fig. 3 shows the results of an experiment in which rats were or were not vaccinated with activated, pressure-treated clones A2b or Zla. The rats were then challenged with M. tuberculosis to induce active adjuvant arthritis, and their delayed-type hypersensitivity responses were measured to A2b or Zia cells. Nonvaccinated control rats showed background delayed-type hypersensitivity reactions to either A2b or Zia cells, whether or not they were suffering from adjuvant arthritis. In contrast, A2b-vaccinated rats, which were resistant to adjuvant arthritis, manifested a specific delayed-type hypersensitivity reaction to A2b cells. Zla-vaccinated rats, which were susceptible to adjuvant arthritis, did not show a delayed-type hypersensitivity reaction to A2b cells above that of background. (17) .
It has been reported (18) that specific resistance to adjuvant arthritis acquired by vaccination with an untreated T-lymphocyte line could be transferred to naive rats using spleen or thymus lymphocytes. Similarly, resistance induced by activated, pressure-treated A2b could also be transferred by the lymphocytes of vaccinated rats.
Another important question is the nature of the signal carried by the immunizing T lymphocytes that induces anti-idiotypic immunity and resistance. As nonactivated T lymphocytes did not effectively stimulate an immune response, it is possible that the antigen receptor, alone or in a resting state, is not a sufficiently immunogenic signal. Activation might be needed to modify the receptor itself or combine it with other molecules dependent on T-lymphocyte activation. The finding that vaccination was potentiated by aggregation produced by chemical cross-linking of membrane components or by disrupting the cytoskeleton suggests that a multimolecular complex might constitute a functional antigenic determinant. For want of suitable strain combinations in rats, we have been unable to explore the question of whether vaccination dan take place across allogeneic barriers. However, the results of preliminary studies of vaccination of mice against experimental autoimmune thyroiditis (19) suggest that vaccination using syngeneic, but not allogeneic T lymphocytes, is effective (unpublished data). This implies that, similar to other types of T-lymphocyte recognition, the response to the vaccine may be restricted by products of the major histocompatibility complex. Be that as it may, it is clear that autoimmune T lymphocytes can be used as specific therapeutic agents in experimental autoimdhunity. The possible application of T-lymphocyte vaccination to clinical autoimmune diseases remains to be explored.
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